NCT05058352Unknown1 期
A Phase I, Open-label，Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS269, in Patients With Advanced Solid Tumor
Zhejiang Hisun Pharmaceutical Co. Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2021年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Dose limiting toxicities (DLT)
研究概览
简要总结
This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years, no gender limit.
- •Patients with advanced solid tumors confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment, or standard treatment is not applicable at this stage.
- •At least one evaluable tumor lesion according to RECIST version 1.
- •The estimated survival time was more than 3 months.
- •The function of all organs was good, the specific indexes were as follows:
- •Blood system (no transfusion or hematopoietic stimulating factor treatment within 14 days) i. #NEUT ≥1.5×109/L ii. PLT ≥90×109/L iii. HGB ≥85g/L Liver function i. TBIL ≤1.5×ULN ii. ALT ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN iii. AST ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN Renal function i. Ccr >50 ml/min（According to Cockcroft-Gault formula） Blood coagulation function i. APTT ≤1.5×ULN ii. INR ≤1.5×ULN
- •The subjects should be informed and agreed to the study before the start of the trial, and sign the written informed consent voluntarily.
排除标准
- •Received anti-tumor treatments within 14 days or less than 5 half-lives (whichever is longer) before the first use of the study drug
- •Received blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor and other treatments within 7 days before receiving blood system examination during the screening period.
- •Received other unmarketed clinical study drugs or treatments within 4 weeks before the first use of the study drug.
- •Major organ surgery (excluding biopsy) or significant trauma occurred within 4 weeks before the first use of the study drug;
- •Systemic administration of glucocorticoids (prednisone > 10 mg / day or equivalent dose of the same drug) or other immunosuppressants within 14 days before the first use of the study drug; except for local, eye, intra articular, nasal and inhaled corticosteroids; short-term use of glucocorticoids for preventive treatment (e.g. prevention of contrast agent allergy)；
- •CYP1A2/P-gp potent inhibitors or potent inducers were used within 7 days before the first use of the study drug；
- •Resistance to selective RET inhibitors;
- •The adverse reactions of previous anti-tumor therapy have not yet recovered to CTCAE 5.0 grade evaluation ≤ 1 (except for the toxicity without safety risk judged by researchers such as alopecia)；
- •Patients with central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that the central nervous system metastasis or meningeal metastasis has not been controlled, which is not suitable for the study.
- •Have active infection and need systemic anti infection therapy；
- •Have a history of immunodeficiency, including HIV antibody test positive；
- •Active hepatitis B, allowing preventive antiviral treatment other than interferon; hepatitis C virus infection；
- •Present or past interstitial lung disease (except radiation-induced pulmonary fibrosis without hormone therapy)；
- •Poorly controlled diabetic patients.
- •Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:
- •Serious abnormal cardiac rhythm or conduction, such as ventricular arrhythmia, Ⅱ - Ⅲ degree atrioventricular block, etc;
- •In the resting state, average QTcF≥480ms in 12 lead -ECG；
- •Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular events of grade 3 or above occurred within 6 months before the first administration;
- •NYHA ≥II or LVEF<50％；
- •Hypertension beyond clinical control；
- •Could not take medication orally，or have severe gastrointestinal obstruction (such as gastrointestinal obstruction, gastrointestinal absorption)；
- •The third space effusion, which could not be controlled clinically, was not suitable for the study；
- •Mental disorder or poor compliance；
- •Eligible patients with fertility (male and female) do not agree to use reliable contraceptive methods (abstinence, condom, intrauterine device or ligation) with their partner during the trial and for at least 3 months after the last medication.
- •Female patients have a positive blood pregnancy test within 7 days before enrollment, or breastfeeding women;
- •The subjects were not suitable for the clinical study because of other serious systemic diseases or other reasons according to the investigator 's judgment.
研究组 & 干预措施
HS269
Experimental
Multiple doses of HS269 tablets
干预措施: HS269 (Drug)
结局指标
主要结局
Dose limiting toxicities (DLT)
时间窗: From date of initial dose until up to 33 days for treatment
Incidence rate of dose limiting toxicities (DLT)
Adverse Event(s) and Serious Adverse Event(s)
时间窗: Through study completion or early study discontinuation（up to 12 months）
The occurrence and rate of AE and SAE
次要结局
- ORR(Approximately 12 months)
- DCR(Approximately 12 months)
- PFS(Approximately 12 months)
- Peak Plasma Concentration (Cmax)(From date of initial dose until up to 33 days for treatment)
- Area Under the Plasma Concentration versus Time Curve (AUC)(From date of initial dose until up to 33 days for treatment)
- Calcitonin in Peripheral Blood(Through study completion or early study discontinuation（up to 12 months）)
- Thyroglobulin in Peripheral Blood(Through study completion or early study discontinuation（up to 12 months）)
- Peripheral blood ctDNA(Through study completion or early study discontinuation（up to 12 months）)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.Tumor, SolidNCT06193902Leucid Bio17
招募中
1 期
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsSolid TumorAdvanced Solid TumorSolid Tumor, AdultMetastatic TumorOvarian NeoplasmsOvarian CarcinomaMetastatic Ovarian CarcinomaEndometrial NeoplasmsEndometrial DiseasesMetastatic Endometrial CancerTriple Negative Breast CancerMetastatic Endometrial CarcinomaAdvanced Endometrial CarcinomaAdvanced Ovarian CarcinomaAdvanced Gastric CarcinomaMetastatic Gastric CancerMetastatic Gastric CarcinomaSmall Cell Lung CarcinomaTriple Negative Breast NeoplasmsPlatinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaCCNE1 AmplificationHormone Receptor Negative Breast CarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastProgesterone-receptor-positive Breast CancerOvarian CancerGastric CancerSmall Cell Lung CancerNCT06586957NiKang Therapeutics, Inc.150
已完成
1 期
First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT04622774ImmunoGen, Inc.56
已完成
1 期
A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTICOVID-19NCT05348772Amniotics AB6
已完成
1 期
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsAdvanced Solid Tumor MalignancyNCT04260529Cytovation AS60